Literature DB >> 6029120

Electrical reversion of cardiac arrhythmias.

B Lown.   

Abstract

Entities:  

Mesh:

Year:  1967        PMID: 6029120      PMCID: PMC487824          DOI: 10.1136/hrt.29.4.469

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


× No keyword cloud information.
  40 in total

1.  COMPLICATIONS AND LIMITATIONS OF DIRECT-CURRENT COUNTERSHOCK.

Authors:  M D RABBINO; W LIKOFF; L S DREIFUS
Journal:  JAMA       Date:  1964-11-02       Impact factor: 56.272

2.  COMPARISON OF VENTRICULAR FUNCTION SUBSEQUENT TO MULTIPLE DEFIBRILLATIONS UTILIZING THE ALTERNATING CURRENT AND THE DIRECT CURRENT DEFIBRILLATORS.

Authors:  F B MAIN; E ABERDEEN; F L GERBODE
Journal:  Surg Forum       Date:  1963

3.  PULMONARY OEDEMA FOLLOWING TREATMENT OF ARRHYTHMIAS BY DIRECT-CURRENT SHOCK.

Authors:  L RESNEKOV; L MCDONALD
Journal:  Lancet       Date:  1965-03-06       Impact factor: 79.321

4.  Conversion of atrial fibrillation to sinus rhythm by direct-current shock.

Authors:  S ORAM; J P DAVIES; I WEINBREN; P TAGGART; L D KITCHEN
Journal:  Lancet       Date:  1963-07-27       Impact factor: 79.321

5.  New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge.

Authors:  B LOWN; R AMARASINGHAM; J NEUMAN
Journal:  JAMA       Date:  1962-11-03       Impact factor: 56.272

6.  Lone auricular fibrillation.

Authors:  W EVANS; P SWANN
Journal:  Br Heart J       Date:  1954-04

7.  Systemic arterial embolism in rheumatic heart disease.

Authors:  R DALEY; T W MATTINGLY; C L HOLT; E F BLAND; P D WHITE
Journal:  Am Heart J       Date:  1951-10       Impact factor: 4.749

8.  Interruption of T waves by premature QRS complexes and the relationship of this phenomenon to ventricular fibrillation.

Authors:  D G PALMER
Journal:  Am Heart J       Date:  1962-03       Impact factor: 4.749

9.  Hemodynamic effects after reversion from atrial fibrillation to sinus rhythm by precordial shock.

Authors:  T Killip; R A Baer
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

10.  The use of quinidine in cardioversion.

Authors:  M Rossi; B Lown
Journal:  Am J Cardiol       Date:  1967-02       Impact factor: 2.778

View more
  80 in total

1.  External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements.

Authors:  G L Botto; A Politi; W Bonini; T Broffoni; R Bonatti
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

Review 2.  Cardioversion in atrial fibrillation: indications, thromboembolic prophylaxis, and role of transesophageal echocardiography.

Authors:  M L Main; A L Klein
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Treatment of atrial fibrillation.

Authors:  Y Blaauw; I C Van Gelder; H J G M Crijns
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

4.  Design and preliminary data of the Metrix Atrioverter expanded indication trial.

Authors:  C Timmermans; L M Rodriguez; G M Ayers; A Siu; J Smeets; P Barenbrug; H J Wellens
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

5.  Sick sinus syndrome in children.

Authors:  O Scott; F J Macartney; P B Deverall
Journal:  Arch Dis Child       Date:  1976-02       Impact factor: 3.791

6.  Genetics of sick sinus syndrome.

Authors:  Jeffrey B Anderson; D Woodrow Benson
Journal:  Card Electrophysiol Clin       Date:  2010-12-01

7.  eHEART: www.heartjnl.com.

Authors: 
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

Review 8.  Management of Supraventricular Tachycardia in Infants.

Authors:  Chalese Richardson; Eric S Silver
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 9.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Hemodynamic effects after conversion of arrhythmias.

Authors:  R J Corliss; D H McKenna; C W Crumpton; G G Rowe
Journal:  J Clin Invest       Date:  1968-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.